B. Braun Introduces New Ready-to-Activate Cefazolin 3g Pre-Mix for Enhanced Patient Care
B. Braun Medical Inc. recently unveiled its latest product innovation, the Cefazolin 3g pre-mix, which is now available in the state-of-the-art DUPLEX® containers. This advancement aims to optimize patient care, particularly for those undergoing surgical procedures or at elevated risk of infections. Cefazolin, a commonly prescribed antibiotic, is utilized to prevent infections before, during, or after surgery. The addition of the 3g dosage complements the existing offerings of 1g and 2g formulations, targeting patients who weigh 120 kg or more.
One of the standout features of the Cefazolin 3g in DUPLEX containers is its design. The DUPLEX Container consists of a two-compartment, flexible IV system that keeps the medication and the diluent separate until the moment of administration. This ready-to-activate feature simplifies the process for healthcare professionals, ensuring that they can deliver precise dosages with minimal effort and time.
Healthcare providers can benefit from the ease of use that DUPLEX containers offer, which can be stocked at room temperature and have a shelf life of up to 18 months. This convenience eliminates the complexities often associated with reconstitution or thawing, allowing clinicians to focus on what matters most: patient care. Shawn Brinson, Director of Marketing for Injectable Drugs at B. Braun, stated, "We are excited to add Cefazolin 3g to our portfolio, addressing a previously unmet need for larger patients. The DUPLEX system provides a solution that is both user-friendly and reduces potential for dosing errors."
When the time comes to administer the Cefazolin 3g, caregivers simply follow a straightforward process: fold, squeeze, and shake the container to mix. With integrated barcode technology for final admixture, along with lot identification and expiration tracking, this system also helps in automating patient charting and managing inventory, further increasing efficiency within healthcare settings.
B. Braun’s commitment to high-quality patient care extends beyond the surface with its robust infrastructure. The company is headquartered in Bethlehem, Pennsylvania, and employs approximately 8,500 people across North America. An integral part of the B. Braun Group of Companies, B. Braun is dedicated to supporting healthcare systems by continuously enhancing both provider and patient experiences.
With over 64,000 employees globally, B. Braun champions its 'Sharing Expertise®' philosophy, positioning itself as a thought leader and partner in the healthcare industry. This approach reinforces their mission to improve care while simultaneously lowering costs, addressing the critical issues faced by health systems today.
In sum, the introduction of their Cefazolin 3g pre-mix in the innovative DUPLEX container represents a significant advancement in the field of smart infusion therapy and pain management. As B. Braun continues to lead in medical technology, healthcare workers can look forward to simplified processes, reduced errors, and ultimately, more effective patient care. The future of patient-administered medications looks promising with B. Braun's ongoing commitment to excellence in the medical sector.
One of the standout features of the Cefazolin 3g in DUPLEX containers is its design. The DUPLEX Container consists of a two-compartment, flexible IV system that keeps the medication and the diluent separate until the moment of administration. This ready-to-activate feature simplifies the process for healthcare professionals, ensuring that they can deliver precise dosages with minimal effort and time.
Healthcare providers can benefit from the ease of use that DUPLEX containers offer, which can be stocked at room temperature and have a shelf life of up to 18 months. This convenience eliminates the complexities often associated with reconstitution or thawing, allowing clinicians to focus on what matters most: patient care. Shawn Brinson, Director of Marketing for Injectable Drugs at B. Braun, stated, "We are excited to add Cefazolin 3g to our portfolio, addressing a previously unmet need for larger patients. The DUPLEX system provides a solution that is both user-friendly and reduces potential for dosing errors."
When the time comes to administer the Cefazolin 3g, caregivers simply follow a straightforward process: fold, squeeze, and shake the container to mix. With integrated barcode technology for final admixture, along with lot identification and expiration tracking, this system also helps in automating patient charting and managing inventory, further increasing efficiency within healthcare settings.
B. Braun’s commitment to high-quality patient care extends beyond the surface with its robust infrastructure. The company is headquartered in Bethlehem, Pennsylvania, and employs approximately 8,500 people across North America. An integral part of the B. Braun Group of Companies, B. Braun is dedicated to supporting healthcare systems by continuously enhancing both provider and patient experiences.
With over 64,000 employees globally, B. Braun champions its 'Sharing Expertise®' philosophy, positioning itself as a thought leader and partner in the healthcare industry. This approach reinforces their mission to improve care while simultaneously lowering costs, addressing the critical issues faced by health systems today.
In sum, the introduction of their Cefazolin 3g pre-mix in the innovative DUPLEX container represents a significant advancement in the field of smart infusion therapy and pain management. As B. Braun continues to lead in medical technology, healthcare workers can look forward to simplified processes, reduced errors, and ultimately, more effective patient care. The future of patient-administered medications looks promising with B. Braun's ongoing commitment to excellence in the medical sector.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.